<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607112443260</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607112443260</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Impact of Refeeding on Blood Fatty Acids and Amino Acid Profiles in Elderly Patients</article-title>
<subtitle>A Metabolomic Analysis</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Dror</surname><given-names>Yosef</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0148607112443260">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Almashanu</surname><given-names>Shlomo</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-0148607112443260">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lubart</surname><given-names>Emilia</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0148607112443260">3</xref>
<xref ref-type="aff" rid="aff4-0148607112443260">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sela</surname><given-names>Ben-Ami</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff4-0148607112443260">4</xref>
<xref ref-type="aff" rid="aff5-0148607112443260">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shimoni</surname><given-names>Liron</given-names></name>
<degrees>MSc, RD</degrees>
<xref ref-type="aff" rid="aff1-0148607112443260">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Segal</surname><given-names>Refael</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0148607112443260">3</xref>
<xref ref-type="aff" rid="aff4-0148607112443260">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607112443260"><label>1</label>School of Nutrition, Faculty of Agriculture, The Hebrew University of Jerusalem, Rehovot, Tel-Hashomer, Israel</aff>
<aff id="aff2-0148607112443260"><label>2</label>Department of Community Genetics, Israeli Ministry of Health, Tel-Hashomer, Israel</aff>
<aff id="aff3-0148607112443260"><label>3</label>Geriatric Medical Center, Shmuel Harofeh, Beer Yaakov, Israel</aff>
<aff id="aff4-0148607112443260"><label>4</label>The Sackler Faculty of Medicine, Tel Aviv University, Israel</aff>
<aff id="aff5-0148607112443260"><label>5</label>Institute of Chemical Pathology, Sheba Medical Center, Tel-Hashomer, Israel</aff>
<author-notes>
<corresp id="corresp1-0148607112443260">Yosef Dror, PhD, School of Nutrition, Faculty of Agriculture, The Hebrew University of Jerusalem, Rehovot, Israel. Email: <email>Israeldror@huji.ac.il</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>37</volume>
<issue>1</issue>
<fpage>109</fpage>
<lpage>116</lpage>
<history>
<date date-type="received">
<day>20</day>
<month>4</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>2</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>: Refeeding of elderly frail patients after food deprivation is commonly associated with a high mortality rate. <italic>Objective</italic>: To evaluate the effect of refeeding on metabolite fluctuation of blood carnitine fatty acids (15 compounds) and free amino acids (14 compounds). <italic>Methods</italic>: Metabolite fluctuation was followed up in an exploratory, cohort, and noninterventional study in elderly and frail patients (84.5 ± 5 years) after a long period of food deprivation. Patients in the study group were refed by enteral nutrition (EN) and were followed up during 7 days for blood metabolites (n = 27). Patients in the control group (n = 26) had been fed by EN for more than 3 months. Refeeding was initiated with 10 kcal/kg/d and gradual increases of 200 kcal/d for 3 days afterwards. Blood metabolites were assayed in a sample of 25 µL. <italic>Results</italic>: On food deprivation, the concentrations of all even monocarboxylic carnitine fatty acids were much higher in the study group than in the EN control group (<italic>P</italic> &lt; .01). Upon refeeding, a remarkable decrease in all carnitine fatty acids was observed. In addition, significant daily fluctuations were observed for most metabolites in the study group of the refed patients as compared with the EN control group (<italic>P</italic> &lt; .01). The highest fluctuations were observed following refeeding in the 7 patients who later died. <italic>Conclusion</italic>: A significant metabolic instability is observed on refeeding even with a slow refeeding schedule of 10 kcal/kg/d. Measurement of metabolomics parameters may be used for the evaluation of malnutrition, refeeding status, and optimization of the enteral formula.</p>
</abstract>
<kwd-group>
<kwd>refeeding</kwd>
<kwd>metabolome</kwd>
<kwd>food deprivation</kwd>
<kwd>carnitine fatty acids</kwd>
<kwd>guidelines</kwd>
<kwd>malnutrition</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607112443260">
<title>Clinical Relevancy Statement</title>
<p>Measurement of blood concentrations of the even carnitine fatty acids (C2–C18) might assist us in evaluating the malnutrition status and considering the refeeding schedule.</p>
</sec>
<sec id="section2-0148607112443260" sec-type="intro">
<title>Introduction</title>
<p>Enteral nutrition (EN) helps sustain life in patients with different causes of pharyngeal dysphagia by allowing patients access to fluids, food, and drugs. Nowadays, more than 1 million patients in Western countries rely on EN products, with a forecast of 7.4% annual growth.<sup><xref ref-type="bibr" rid="bibr1-0148607112443260">1</xref></sup> The decision to initiate EN in malnourished patients involves the assessment of many complicated issues, including ethics. Without a careful assessment process for patient selection and developing an optimal, patient-specific monitoring plan, serious adverse events such as refeeding syndrome can result.<sup><xref ref-type="bibr" rid="bibr2-0148607112443260">2</xref></sup> One of the main clinical problems is refeeding syndrome.</p>
<p>Refeeding syndrome was first described among people released from concentration camps at the end of World War II, when some survivors died after beginning oral uncontrolled eating.<sup><xref ref-type="bibr" rid="bibr3-0148607112443260">3</xref></sup> At present, the greatest number of people affected by the refeeding syndrome is seen in the food-deprived populations in Third World countries, particularly in children admitted to the rehabilitation centers.<sup><xref ref-type="bibr" rid="bibr4-0148607112443260">4</xref></sup> In the most developed Western countries, the predisposed cases to refeeding syndrome are patients with chronic undernutrition due to anorexia nervosa, alcohol addiction, and advanced cancers; postoperative patients; and the elderly, with food deprivation due to dementia or acute general deterioration.<sup><xref ref-type="bibr" rid="bibr5-0148607112443260">5</xref>,<xref ref-type="bibr" rid="bibr6-0148607112443260">6</xref></sup> One of the accepted diagnostic criteria for refeeding syndrome includes an observed reduction of serum phosphorus to &lt;0.5 mM (1.6 mg/dL) after the initiation of feeding in the absence of other causes of hypophosphatemia.<sup><xref ref-type="bibr" rid="bibr5-0148607112443260">5</xref></sup> However, a direct correlation between mortality and hypophosphatemia has not been established in patients with refeeding syndrome.<sup><xref ref-type="bibr" rid="bibr5-0148607112443260">5</xref>,<xref ref-type="bibr" rid="bibr7-0148607112443260">7</xref></sup> Decreased potassium and magnesium levels support the diagnosis. However, the changes in these electrolytes are only the tip of the iceberg of all metabolites affected by the refeeding syndrome. Refeeding syndrome is also characterized by fluid retention and dysfunction of various organ and systems, which can result in significant morbidity.<sup><xref ref-type="bibr" rid="bibr8-0148607112443260">8</xref>,<xref ref-type="bibr" rid="bibr9-0148607112443260">9</xref></sup> In our previous prospective study in frail elderly patients, we found a mortality incidence of 23% in the first week and 48% in the month following initiation of EN.<sup><xref ref-type="bibr" rid="bibr5-0148607112443260">5</xref></sup> The main cause of death was related to infections complications and their underlying disease states.</p>
<p>These are old patients in a poor general condition, demented, bedridden, and many with decubitus ulcers and recurrent infections. These patients naturally have a limited life expectancy.</p>
<p>Fatty acids must bind with a carinitine molecule to be metabolized through β-oxidation in the mitochondrion or the peroxisome, but the acyl-carnitines comprise only 0.04% of the whole blood lipids.<sup><xref ref-type="bibr" rid="bibr10-0148607112443260">10</xref></sup> There are 3 main fractions of blood lipids—namely, total blood lipids (mainly glycerides), free fatty acids, and carnitine fatty acids, with the following concentrations (mg/L): 1500, 100, and 0.6, respectively. Acetylcarnitine (C2) comprises about 60% of the fraction of carnitine fatty acids.<sup><xref ref-type="bibr" rid="bibr11-0148607112443260">11</xref></sup> Because of their crucial role in immediate metabolism, carnitine fatty acids and their kinetics could serve as a good indicator for metabolite fluctuations. The routine use of mass spectroscopy (MS) for the analysis of carnitine fatty acids and amino acids from a blood drop in newborns enabled us to investigate the metabolic kinetics of these metabolites following initiating refeeding. Fatty acid metabolism is the main fuel supply upon food deprivation, but the selectivity of these pathways for any substrate has not yet been tested experimentally.<sup><xref ref-type="bibr" rid="bibr12-0148607112443260">12</xref><xref ref-type="bibr" rid="bibr13-0148607112443260"/>-<xref ref-type="bibr" rid="bibr14-0148607112443260">14</xref></sup></p>
<p>Evaluation of the metabolomic fluctuations in patients after refeeding might assist and optimize the refeeding schedule and the formula composition, as well as probably help us understand the causes of the deterioration of cellular activities that eventually lead to mortality. The metabolic evaluation performed in the present study is also relevant to all cases of malnutrition in many hospitalized patients.<sup><xref ref-type="bibr" rid="bibr15-0148607112443260">15</xref></sup></p>
<p>Refeeding of a frail patient produces one of the most dramatic variations of substrate flows in humans, which affects almost all metabolic cycles. With the newer techniques of molecule quantification, such flow induction gives us a unique opportunity to observe metabolomic fluctuations that occur in human with 3 outcomes: (1) improved indications for the examined patient, (2) better guidelines for refeeding, and (3) a wide window into the human metabolome under high pressure. In the present study, we evaluate only a narrow strip of the metabolome with a wide opportunity for the future.</p>
</sec>
<sec id="section3-0148607112443260" sec-type="methods">
<title>Methods</title>
<sec id="section4-0148607112443260">
<title>Study Setting and Patients</title>
<p>Hospitalized geriatric patients in 3 acute geriatric and 4 skilled nursing wards (total 300 beds) were included in this study. An exploratory and cohort study was designed in which the study group (n = 27) comprised patients indicated for refeeding by EN after prolonged periods of food deprivation (mean 10 ± 12 days; range, 3–65) due to feeding difficulties. The patients were evaluated within 7 days after commencing refeeding. The EN control group (n = 26) comprised patients fed by EN for more than 3 months hospitalized in the same wards.</p>
<p>Randomization was met by including every patient who underwent refeeding and met the inclusion and the exclusion criteria. Because of the high mortality rate on refeeding, no real randomization could be fulfilled for these 2 groups.</p>
<p>Patients in a critically clinical situation due to sepsis, dehydration or electrolyte disturbances, liver disease and renal failure, widespread metastatic disease, or severe decubitus ulcers (grade 3 and above) were excluded from both groups.</p>
<p>The study was approved by the local ethics committee, and informed consent was obtained from the closest family member.</p>
</sec>
<sec id="section5-0148607112443260">
<title>Refeeding Management</title>
<p>Special attention was paid by a multidisciplinary staff, including physicians, nursing staff, and dieticians, to assess nutrition status during the malnutrition period. Initiation of EN was decided by the same team. Nasogastric tube is the preferred procedure in Israel for initiating refeeding.<sup><xref ref-type="bibr" rid="bibr16-0148607112443260">16</xref></sup> The Short Nutritional Assessment Questionnaire (SNAQ) is the primary evaluation method of the dietitian’s team in our hospital.<sup><xref ref-type="bibr" rid="bibr17-0148607112443260">17</xref></sup> The recorded energy intake for the study group (mean of the last 3 days before insertion of EN) was 187 ± 212 kcal/d, but the amount spitted out could not be evaluated, and therefore the actual energy intake was probably lower.</p>
<p>The feeding was provided by the clinical dietician and was based on the Easy-fiber formula (Easyline, Caesarea, Israel) containing 1100 kcal/L with energy composition of 16% protein, 55% carbohydrates, and 29% fat. The formula also contained fiber (14 g/L). Refeeding was initiated with 10 kcal/kg/d and with increases of 200 kcal each 3 days afterward. The amount of protein was 1.2–1.5 g/kg/d. Relevant clinical parameters, morbidity, and medical treatment were recorded. For body mass index (BMI) calculation, height was estimated according to knee height. Relevant laboratory parameters were examined before and after starting of feeding, including blood count and biochemical parameters with special attention to phosphorus, potassium, and magnesium levels.</p>
</sec>
<sec id="section6-0148607112443260">
<title>Blood Collection for Metabolomics Assays</title>
<p>Blood for the study group was collected on the morning before refeeding, when the patient was actually on food deprivation, and daily afterwards, before the morning meal, for 7 days from EN commencement. Similarly, for the EN control group, blood samples were performed daily for 1 week. Routine clinical and laboratory measurements of refeeding were performed as indicated by the physician in charge.</p>
<p>A free-flowing blood drop, from a finger prick, was spotted onto a Guthrie filter paper until saturation. Blood spots were dried for at least 4 hours (dried blood spot [DBS]). Thus, 2 groups were evaluated during 7 days: study group (n = 27 patients) and EN control group (n = 26 patients). Blood samples were also collected from some other patients for the evaluation of a diurnal effect or day-to-day fluctuation.</p>
</sec>
<sec id="section7-0148607112443260">
<title>Chemical Assays</title>
<p>Concentrations of 15 carnitine fatty acids, free carnitine, and 14 amino acids were measured from DBS extract, in duplicates, by tandem mass spectrometry (MS/MS; Waters micromass MS technologies, Quattro Premier XE; Waters Corp, Milford, MA), which is routinely been used by the Israeli National Newborn Screening Program. Using a nonderivatized method, punched DBS measuring 1/8 of an inch was placed into a 96-well plate (polypropylene Nunc), and 200 µL extraction solution (80% acetonitrile, 20% doubly distilled water, and 0.02% formic acid) containing internal standards (NSK-AB; Cambridge Isotope Laboratories [CIL], Andover, MA) was added to each well. The plate was covered, incubated, and revolved 750 times per minute at room temperature for 30 minutes. After being transferred to a new 96-well plate (leaving behind the DBS filter paper), the liquid was directly injected (30 µL) into the MS/MS system (mobile phase containing 80% acetonitrile, 20% doubly distilled water, and 0.02% formic acid). Concentrations were calculated using “Neolynx” software.<sup><xref ref-type="bibr" rid="bibr18-0148607112443260">18</xref></sup></p>
<p>Metabolites with the same molecular weight were detected together—namely, alanine and sarcosine. In normal conditions, sarcosine comprises about the same concentration of alanine, but in a catabolic state, sarcosine may be increased. Leucine, isoleucine, and hydroxyproline had ratios of about 65, 29, and 6, respectively, but the catabolic state may have increased hydroxyproline. Ornithine and asparagine had ratios of about 60 and 40, respectively.<sup><xref ref-type="bibr" rid="bibr11-0148607112443260">11</xref></sup> While ornithine is circulating in the urea cycle and not circulating in protein turnover, asparagine is circulating in protein turnover. Isomers of fatty acids were also detected together, such as butyric and isobutyric acids or valeric and isovaleric acids. These isomeric compounds may be derived from amino acid transamination. Replacement figures were calculated according to the surrounding values (nearby days and various metabolites of the same sample) for the missing plot data of glycine because of detection limitation due to its low molecular weight. Metabolites were also categorized. For the validation of the metabolite values, we also present values for newborns.</p>
</sec>
<sec id="section8-0148607112443260">
<title>Statistics</title>
<p>Statistical analysis was carried out by SPSS software version 17 (SPSS, Inc, an IBM Company, Chicago, IL). Continuous variables were analyzed by analysis of variance (ANOVA; <xref ref-type="table" rid="table2-0148607112443260">Table 2</xref>) and by the Student <italic>t</italic> test (all other tables) with 2 tails.</p>
</sec>
</sec>
<sec id="section9-0148607112443260" sec-type="results">
<title>Results</title>
<p><xref ref-type="table" rid="table1-0148607112443260">Table 1</xref> shows the demographic information and baseline characteristics of the study patients. Energy intake is the only parameter that is different between the 2 groups. Routine laboratory data are shown in <xref ref-type="table" rid="table2-0148607112443260">Table 2</xref>. Baseline values and the means within the week following EN commencement are shown for the study group. The most significant differences were observed for blood albumin and phosphate levels, and interestingly, both decreased following initiation of refeeding. Hypophosphatemia (&lt;2.7 mg/dL) was observed in 15 (56%) patients, and severe hypophosphatemia (&lt;1.6 mg/dL) was observed in 4 (15%) patients within 7 days following EN commencement.</p>
<table-wrap id="table1-0148607112443260" position="float">
<label>Table 1.</label>
<caption>
<p>Demographics of Patients in the Refeeding Study.</p>
</caption>
<graphic alternate-form-of="table1-0148607112443260" xlink:href="10.1177_0148607112443260-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Study Group</th>
<th align="center">EN Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>27</td>
<td>26</td>
</tr>
<tr>
<td>Age, y, mean ± SD</td>
<td>84.5 ± 5</td>
<td>82.5 ± 6</td>
</tr>
<tr>
<td>Female/male, No.</td>
<td>16/11</td>
<td>16/10</td>
</tr>
<tr>
<td>Weight, kg, mean ± SD</td>
<td>56.5 ± 9.5</td>
<td>60.7 ± 11.4</td>
</tr>
<tr>
<td>Body mass index, mean ± SD</td>
<td>23.0 ± 4.4</td>
<td>24.6 ± 4.9</td>
</tr>
<tr>
<td>Days of food deprivation</td>
<td>12 ± 13</td>
<td>0</td>
</tr>
<tr>
<td> Range</td>
<td>3–65</td>
<td/>
</tr>
<tr>
<td colspan="3">Comorbidity, %</td>
</tr>
<tr>
<td> Dementia</td>
<td>85</td>
<td>92</td>
</tr>
<tr>
<td> Cerebrovascular accident</td>
<td>56</td>
<td>62</td>
</tr>
<tr>
<td> Anemia (hemoglobin &lt;12 g)</td>
<td>48</td>
<td>46</td>
</tr>
<tr>
<td> Ischemic heart disease</td>
<td>56</td>
<td>62</td>
</tr>
<tr>
<td> Urinary catheter</td>
<td>67</td>
<td>85</td>
</tr>
<tr>
<td> Decubitus ulcer</td>
<td>37</td>
<td>46</td>
</tr>
<tr>
<td> Congestive heart failure</td>
<td>30</td>
<td>27</td>
</tr>
<tr>
<td> Diabetes</td>
<td>19</td>
<td>15</td>
</tr>
<tr>
<td>Energy intake, kcal/d, mean ± SD</td>
<td>187 ± 212 (0–565)<sup><xref ref-type="table-fn" rid="table-fn2-0148607112443260">a</xref></sup></td>
<td>1785 ± 219</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607112443260">
<p>Except for energy intake, no statistical differences between the groups were observed. EN, enteral nutrition.</p>
</fn>
<fn id="table-fn2-0148607112443260">
<label>a</label>
<p>Average and range for 3 days consecutive days before EN commencement.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0148607112443260" position="float">
<label>Table 2.</label>
<caption>
<p>Blood Parameters of the Study Group, Before and 7 Days After EN Commencement, Compared With EN Control.</p>
</caption>
<graphic alternate-form-of="table2-0148607112443260" xlink:href="10.1177_0148607112443260-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="2">Study Group<hr/></th>
<th/>
</tr>
<tr>
<th/>
<th align="center">On Food Deprivation</th>
<th align="center">7 Days After EN Insertion</th>
<th align="center">EN Control Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin, g/dL</td>
<td>11.3 ± 1.7<sup>b</sup></td>
<td>10.1 ± 1.3<sup>a</sup></td>
<td>11.5 ± 1.5<sup>b</sup></td>
</tr>
<tr>
<td>Urea, mg/dL</td>
<td>60.2 ± 39.5</td>
<td>55.3 ± 38.5</td>
<td>54.8 ± 35.2</td>
</tr>
<tr>
<td>Creatinine, mg/dL</td>
<td>1.16 ± 0.56</td>
<td>1.28 ± 0.61</td>
<td>1.06 ± 0.45</td>
</tr>
<tr>
<td>Sodium, mEq/L</td>
<td>141.6 ± 6.13<sup>b</sup></td>
<td>138.7 ± 5.57<sup>a</sup></td>
<td>138.6 ± 3.21<sup>a</sup></td>
</tr>
<tr>
<td>Potassium, mEq/L</td>
<td>4.12 ± 0.65<sup>a</sup></td>
<td>4.42 ± 0.78<sup>b</sup></td>
<td>4.21 ± 0.53</td>
</tr>
<tr>
<td>Calcium, mg/dL</td>
<td>8.99 ± 1.47</td>
<td>8.89 ± 1.00</td>
<td>9.17 ± 0.45</td>
</tr>
<tr>
<td>Phosphate, mg/dL</td>
<td>3.07 ± 0.66<sup>b</sup></td>
<td>2.33 ± 0.71<sup>a</sup></td>
<td>3.12 ± 0.76</td>
</tr>
<tr>
<td>Magnesium, mg/dL</td>
<td>1.95 ± 0.31</td>
<td>2.14 ± 0.28</td>
<td>2.60 ± 025</td>
</tr>
<tr>
<td>Albumin, g/dL</td>
<td>2.99 ± 0.49<sup>a</sup></td>
<td>2.66 ± 0.37 <sup>a</sup></td>
<td>3.46 ± 0.47<sup>b</sup></td>
</tr>
<tr>
<td>Cholesterol, mg/dL</td>
<td>165 ± 51<sup>b</sup></td>
<td>132 ± 8<sup>a</sup></td>
<td>159 ± 51</td>
</tr>
<tr>
<td>Triglycerides, mg/dL</td>
<td>138 ± 83</td>
<td>133 ± 58</td>
<td>116 ± 37</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0148607112443260">
<p>Values are means ± SD. Significant differences (<italic>P</italic> &lt; .05) by analysis of variance shown by different superscripts. EN, enteral nutrition.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section10-0148607112443260">
<title>Effects of Feeding (Meals) and Daily Variations on Blood Metabolites</title>
<p>These effects were studied in patients with long-term EN feeding. No significant differences were observed for most of the carnitine fatty acid concentrations in the blood between fasting morning values and postprandial values, which were assayed 2–4 hours after meal. Only the concentrations of glutaric acid increased significantly 4 hours after the meal. Amino acid concentrations showed minor fluctuations during 4 hours after meal. Evaluations of day-to-day fluctuations of both carnitine fatty acids and amino acids showed only slight variations between any 2 consecutive days, with none reaching statistical significance (data not presented).</p>
</sec>
<sec id="section11-0148607112443260">
<title>Effects of Food Deprivation on Blood Metabolites</title>
<p><xref ref-type="table" rid="table3-0148607112443260">Table 3</xref> shows the results of baseline metabolites in the study group as compared with the EN control group. The concentrations of all even monocarboxylic carnitine fatty acids were much higher in the study group on food deprivation than in the EN control group (<italic>P</italic> &lt; .01). Remarkably higher were the ratios for C2 and also for C6–C12. Acetylcarnitine (C2) was the most affected compound. This carnitine fatty acid comprised 74% of all carnitine fatty acids in the food deprivation state but only 62% in the EN control group. The concentrations of the free amino acids were not significantly different between the 2 groups except for methionine, which was higher on food deprivation with a ratio of 1.4 (<italic>P</italic> &lt; .01).</p>
<table-wrap id="table3-0148607112443260" position="float">
<label>Table 3.</label>
<caption>
<p>Blood Metabolites of the Study Group (Baseline) and the EN Control Group.</p>
</caption>
<graphic alternate-form-of="table3-0148607112443260" xlink:href="10.1177_0148607112443260-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Study Group,<sup><xref ref-type="table-fn" rid="table-fn5-0148607112443260">a</xref></sup> µM</th>
<th align="center">EN Control Group, µM</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn6-0148607112443260">b</xref></sup></th>
<th align="center">Ratio<sup><xref ref-type="table-fn" rid="table-fn6-0148607112443260">b</xref></sup></th>
<th align="center">Newborns, µM</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.</td>
<td>27</td>
<td>26</td>
<td/>
<td/>
<td>13,000</td>
</tr>
<tr>
<td colspan="6">Even short-chain acylcarnitines</td>
</tr>
<tr>
<td> C2 acetic</td>
<td>8.67 ± 3.65</td>
<td>3.79 ± 4.11</td>
<td>&lt;.01</td>
<td>2.3</td>
<td>18.4 ± 9.1</td>
</tr>
<tr>
<td> C4 butyric</td>
<td>0.253 ± 0.12</td>
<td>0.180 ± 0.087</td>
<td>&lt;.02</td>
<td>1.4</td>
<td>0.25 ± 0.17</td>
</tr>
<tr>
<td> C6 caproic</td>
<td>0.068 ± 0.043</td>
<td>0.030 ± 0.013</td>
<td>&lt;.01</td>
<td>2.3</td>
<td>0.030 ± 0.020</td>
</tr>
<tr>
<td colspan="6">Medium-chain acylcarnitines</td>
</tr>
<tr>
<td> C8 caprilic</td>
<td>0.136 ± 0.074</td>
<td>0.043 ± 0.032</td>
<td>&lt;.01</td>
<td>3.2</td>
<td>0.110 ± 0.050</td>
</tr>
<tr>
<td> C10 capric</td>
<td>0.194 ± 0.126</td>
<td>0.057 ± 0.049</td>
<td>&lt;.01</td>
<td>3.4</td>
<td>0.110 ± 0.06</td>
</tr>
<tr>
<td> C10:1</td>
<td>0.140 ± 0.068</td>
<td>0.046 ± 0.032</td>
<td>&lt;.01</td>
<td>3.0</td>
<td>0.080 ± 0.040</td>
</tr>
<tr>
<td> C12 lauric</td>
<td>0.031 ± 0.02</td>
<td>0.014 ± 0.007</td>
<td>&lt;.01</td>
<td>2.2</td>
<td>0.060 ± 0.030</td>
</tr>
<tr>
<td> C14 myristic</td>
<td>0.089 ± 0.041</td>
<td>0.059 ± 0.033</td>
<td>&lt;.01</td>
<td>1.5</td>
<td>0.180 ± 0.070</td>
</tr>
<tr>
<td> C14:1</td>
<td>0.049 ± 0.035</td>
<td>0.027 ± 0.01</td>
<td>&lt;.01</td>
<td>1.8</td>
<td>0.070 ± 0.040</td>
</tr>
<tr>
<td colspan="6">Long-chain acylcarnitines</td>
</tr>
<tr>
<td> C16 palmitic</td>
<td>0.87 ± 0.4</td>
<td>0.59 ± 0.24</td>
<td>&lt;.01</td>
<td>1.5</td>
<td>3.04 ± 1.09</td>
</tr>
<tr>
<td> C18 stearic</td>
<td>0.47 ± 0.18</td>
<td>0.28 ± 0.14</td>
<td>&lt;.01</td>
<td>1.7</td>
<td>0.90 ± 0.31</td>
</tr>
<tr>
<td colspan="6">Odd short-chain acylcarnitines</td>
</tr>
<tr>
<td> C3 propionic</td>
<td>0.58 ± 0.34</td>
<td>0.65 ± 0.55</td>
<td>.56</td>
<td>0.9</td>
<td>1.99 ± 0.99</td>
</tr>
<tr>
<td> C5 valeric</td>
<td>0.198 ± 0.115</td>
<td>0.191 ± 0.090</td>
<td>.82</td>
<td>1.1</td>
<td>0.100 ± 0.070</td>
</tr>
<tr>
<td colspan="6">Dicarboxylic acylcarnitines</td>
</tr>
<tr>
<td> Malonic (C3)</td>
<td>0.236 ± 0.137</td>
<td>0.108 ± 0.066</td>
<td>&lt;.01</td>
<td>2.2</td>
<td>0.160 ± 0.070</td>
</tr>
<tr>
<td> Glutaric (C5)</td>
<td>0.094 ± 0.061</td>
<td>0.068 ± 0.035</td>
<td>.06</td>
<td>1.4</td>
<td>0.090 ± 0.070</td>
</tr>
<tr>
<td> Carnitine, free</td>
<td>25.4 ± 11.1</td>
<td>21.0 ± 8.0</td>
<td>.11</td>
<td>1.2</td>
<td>14.2 ± 6.4</td>
</tr>
<tr>
<td colspan="6">Amino acids</td>
</tr>
<tr>
<td> Gly</td>
<td>303 ± 154</td>
<td>294 ± 107</td>
<td>.81</td>
<td>1.0</td>
<td>321 ± 95</td>
</tr>
<tr>
<td> Ala, Sar</td>
<td>214 ± 101</td>
<td>245 ± 71</td>
<td>.21</td>
<td>0.9</td>
<td>265 ± 79</td>
</tr>
<tr>
<td> Val</td>
<td>114 ± 39</td>
<td>111 ± 34</td>
<td>.75</td>
<td>1.0</td>
<td>105 ± 32.7</td>
</tr>
<tr>
<td> Leu, Ile, Hpr</td>
<td>137 ± 54</td>
<td>124 ± 40</td>
<td>.30</td>
<td>1.1</td>
<td>94.7 ± 28.6</td>
</tr>
<tr>
<td> Tyr</td>
<td>58.5 ± 22.5</td>
<td>61.8 ± 17.5</td>
<td>.55</td>
<td>0.9</td>
<td>71.9 ± 26.1</td>
</tr>
<tr>
<td> Phe</td>
<td>59 ± 19.4</td>
<td>56.6 ± 14.8</td>
<td>.62</td>
<td>1.0</td>
<td>49.3 ± 14.0</td>
</tr>
<tr>
<td> Met</td>
<td>9.65 ± 5.21</td>
<td>7.90 ± 4.71</td>
<td>.20</td>
<td>1.2</td>
<td>15.6 ± 4.3</td>
</tr>
<tr>
<td colspan="6">Amino acids circulating in the urea cycle</td>
</tr>
<tr>
<td> Arg</td>
<td>16.8 ± 15.4</td>
<td>15 ± 12.4</td>
<td>.64</td>
<td>1.1</td>
<td>4.79 ± 3.84</td>
</tr>
<tr>
<td> Cit</td>
<td>23.4 ± 15.2</td>
<td>32 ± 16.4</td>
<td>&lt;.05</td>
<td>0.7</td>
<td>10.4 ± 1.34</td>
</tr>
<tr>
<td> Orn, Asn</td>
<td>21.9 ± 14.3</td>
<td>27.5 ± 10.9</td>
<td>.13</td>
<td>0.8</td>
<td>17.6 ± 10.4</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0148607112443260">
<p>Values are means ± SD. Ala, alanine; Arg, arginine; Asn, asparagine; Cit, citrulline; Gly, glycine; Hpr, hydroxyproline; Ile, isoleucine; Leu, leucine; Met, metionine; Orn, ornithine; Phe, phenylalanine; Sar, sarcosine; Tyr, tyrosine; Val, valine.</p>
</fn>
<fn id="table-fn5-0148607112443260">
<label>a</label>
<p>On food deprivation.</p>
</fn>
<fn id="table-fn6-0148607112443260">
<label>b</label>
<p>Statistical difference and ratio between the study group and the enteral nutrition (EN) control group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section12-0148607112443260">
<title>Refeeding Effect</title>
<p>After initiating refeeding, significant fluctuations were observed in almost all blood metabolites (<xref ref-type="table" rid="table4-0148607112443260">Table 4</xref>). Evaluations were performed by paired <italic>t</italic> test, between basal (food deprivation) values and the maximal or minimal values within the 7 days of refeeding. There was a decrease in most acylcarnitines and an increase in most free amino acids (<italic>P</italic> &lt; .01). The concentrations of most free amino acids, except for arginine, increased on refeeding by 1.3- to 2.2-fold. The highest effect of refeeding on the amino acids was observed for methionine (<xref ref-type="table" rid="table4-0148607112443260">Table 4</xref>). The amino acid values increased toward the fourth day, and thereafter a clear decrease was observed (data not presented). An additional evaluation, comparing the 2 study groups for the maximal changes (including baseline) within 1 week, showed significantly higher effects for most metabolites in the refed patients (<xref ref-type="table" rid="table5-0148607112443260">Table 5</xref>).</p>
<table-wrap id="table4-0148607112443260" position="float">
<label>Table 4.</label>
<caption>
<p>Fluctuations in Blood Metabolites for the Study Group: Minimal or the Maximal Values Following Refeeding.</p>
</caption>
<graphic alternate-form-of="table4-0148607112443260" xlink:href="10.1177_0148607112443260-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="5">Study Group<hr/></th>
</tr>
<tr>
<th/>
<th align="center">On Food Deprivation, µM</th>
<th align="center">Minimal Value, µM</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn8-0148607112443260">a</xref></sup></th>
<th align="center">Maximal Value, µM</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn8-0148607112443260">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6">Even short-chain acylcarnitines</td>
</tr>
<tr>
<td> C2 acetic</td>
<td>8.67 ± 3.65</td>
<td>4.19 ± 3.45</td>
<td>&lt;.01</td>
<td>9.78 ± 4.92</td>
<td>.41</td>
</tr>
<tr>
<td> C4 butyric</td>
<td>0.253 ± 0.12</td>
<td>0.161 ± 0.073</td>
<td>&lt;.01</td>
<td>0.326 ± 0.12</td>
<td>.03</td>
</tr>
<tr>
<td> C6 caproic</td>
<td>0.068 ± 0.043</td>
<td>0.034 ± 0.022</td>
<td>&lt;.01</td>
<td>0.081 ± 0.036</td>
<td>.23</td>
</tr>
<tr>
<td colspan="6">Medium-chain acylcarnitines</td>
</tr>
<tr>
<td> C8 caprilic</td>
<td>0.136 ± 0.074</td>
<td>0.064 ± 0.058</td>
<td>&lt;.01</td>
<td>0.164 ± 0.083</td>
<td>.20</td>
</tr>
<tr>
<td> C10 capric</td>
<td>0.194 ± 0.126</td>
<td>0.074 ± 0.052</td>
<td>&lt;.01</td>
<td>0.257 ± 0.146</td>
<td>.10</td>
</tr>
<tr>
<td> C10:1</td>
<td>0.140 ± 0.068</td>
<td>0.057 ± 0.035</td>
<td>&lt;.01</td>
<td>0.173 ± 0.077</td>
<td>.11</td>
</tr>
<tr>
<td> C12 lauric</td>
<td>0.031 ± 0.020</td>
<td>0.011 ± 0.008</td>
<td>&lt;.01</td>
<td>0.036 ± 0.020</td>
<td>.35</td>
</tr>
<tr>
<td> C14 myristic</td>
<td>0.089 ± 0.041</td>
<td>0.054 ± 0.031</td>
<td>&lt;.01</td>
<td>0.108 ± 0.041</td>
<td>.08</td>
</tr>
<tr>
<td> C14:1</td>
<td>0.049 ± 0.035</td>
<td>0.023 ± 0.012</td>
<td>&lt;.01</td>
<td>0.061 ± 0.036</td>
<td>.23</td>
</tr>
<tr>
<td colspan="6">Long-chain acylcarnitines</td>
</tr>
<tr>
<td> C16 palmitic</td>
<td>0.87 ± 0.4</td>
<td>0.59 ± 0.26</td>
<td>&lt;.01</td>
<td>0.96 ± 0.38</td>
<td>.40</td>
</tr>
<tr>
<td> C18 stearic</td>
<td>0.47 ± 0.18</td>
<td>0.31 ± 0.13</td>
<td>&lt;.01</td>
<td>0.51 ± 0.18</td>
<td>.45</td>
</tr>
<tr>
<td colspan="6">Odd short-chain acylcarnitines</td>
</tr>
<tr>
<td> C3 propionic</td>
<td>0.58 ± 0.34</td>
<td>0.44 ± 0.31</td>
<td>.17</td>
<td>0.76 ± 0.39</td>
<td>.08</td>
</tr>
<tr>
<td> C5 valeric</td>
<td>0.198 ± 0.115</td>
<td>0.135 ± 0.072</td>
<td>&lt;.02</td>
<td>0.275 ± 0.121</td>
<td>.02</td>
</tr>
<tr>
<td colspan="6">Dicarboxylic acylcarnitines</td>
</tr>
<tr>
<td> Malonic (C3)</td>
<td>0.236 ± 0.137</td>
<td>0.104 ± 0.063</td>
<td>&lt;.01</td>
<td>0.273 ± 0.152</td>
<td>.35</td>
</tr>
<tr>
<td> Glutaric (C5)</td>
<td>0.094 ± 0.061</td>
<td>0.042 ± 0.044</td>
<td>&lt;.01</td>
<td>0.151 ± 0.083</td>
<td>.01</td>
</tr>
<tr>
<td> Carnitine, free</td>
<td>25.4 ± 11.1</td>
<td>19.4 ± 8.8</td>
<td>&lt;.03</td>
<td>30.0 ± 11.6</td>
<td>.16</td>
</tr>
<tr>
<td colspan="6">Amino acids</td>
</tr>
<tr>
<td> Gly</td>
<td>303 ± 154</td>
<td>192 ± 87</td>
<td>&lt;.01</td>
<td>460 ± 182</td>
<td>.01</td>
</tr>
<tr>
<td> Ala, Sar</td>
<td>214 ± 101</td>
<td>166 ± 62</td>
<td>&lt;.04</td>
<td>354 ± 101</td>
<td>.01</td>
</tr>
<tr>
<td> Val</td>
<td>114 ± 39</td>
<td>84 ± 25</td>
<td>&lt;.01</td>
<td>152 ± 42</td>
<td>.01</td>
</tr>
<tr>
<td> Leu, Ile, Hpr</td>
<td>137 ± 54</td>
<td>86 ± 30</td>
<td>&lt;.01</td>
<td>187 ± 52</td>
<td>.01</td>
</tr>
<tr>
<td> Tyr</td>
<td>58.5 ± 22.5</td>
<td>46.8 ± 18.1</td>
<td>&lt;.04</td>
<td>92.9 ± 31.1</td>
<td>.01</td>
</tr>
<tr>
<td> Phe</td>
<td>59.0 ± 19.4</td>
<td>46.0 ± 14.8</td>
<td>&lt;.01</td>
<td>86.1 ± 29.2</td>
<td>.01</td>
</tr>
<tr>
<td> Met</td>
<td>9.65 ± 5.21</td>
<td>8.02 ± 3.72</td>
<td>.19</td>
<td>15.35 ± 7.21</td>
<td>.01</td>
</tr>
<tr>
<td colspan="6">Amino acids circulating in the urea cycle</td>
</tr>
<tr>
<td> Arg</td>
<td>16.8 ± 15.4</td>
<td>7.6 ± 5.6</td>
<td>&lt;.01</td>
<td>25.7 ± 17.5</td>
<td>.05</td>
</tr>
<tr>
<td> Cit</td>
<td>23.4 ± 15.2</td>
<td>16.9 ± 7.4</td>
<td>&lt;.05</td>
<td>38.7 ± 18.4</td>
<td>.01</td>
</tr>
<tr>
<td> Orn, Asn</td>
<td>21.9 ± 14.3</td>
<td>13.2 ± 10.2</td>
<td>&lt;.02</td>
<td>48.4 ± 36.3</td>
<td>.01</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0148607112443260">
<p>Values are means ± SD. Ala, alanine; Arg, arginine; Asn, asparagine; Cit, citrulline; Gly, glycine; Hpr, hydroxyproline; Ile, isoleucine; Leu, leucine; Met, metionine; Orn, ornithine; Phe, phenylalanine; Sar, sarcosine; Tyr, tyrosine; Val, valine.</p>
</fn>
<fn id="table-fn8-0148607112443260">
<label>a</label>
<p>Differences between baseline (on food deprivation) and minimal or maximal values within 1 week following refeeding.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-0148607112443260" position="float">
<label>Table 5.</label>
<caption>
<p>Maximal Fluctuations of Blood Metabolites in the Study Group in Comparison to the EN Control Group Within 7 Days of Follow-Up.</p>
</caption>
<graphic alternate-form-of="table5-0148607112443260" xlink:href="10.1177_0148607112443260-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Study Group, µM</th>
<th align="center">EN Control Group, µM</th>
<th align="center"><italic>P</italic> Value<sup><xref ref-type="table-fn" rid="table-fn10-0148607112443260">a</xref></sup></th>
<th align="center">Ratio<sup><xref ref-type="table-fn" rid="table-fn10-0148607112443260">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="5">Even short-chain acylcarnitines</td>
</tr>
<tr>
<td> C2 acetic</td>
<td>5.59 ± 3.16</td>
<td>1.63 ± 1.91</td>
<td>&lt;.01</td>
<td>3.4</td>
</tr>
<tr>
<td> C4 butyric</td>
<td>0.166 ± 0.09</td>
<td>0.094 ± 0.09</td>
<td>&lt;.01</td>
<td>1.8</td>
</tr>
<tr>
<td> C6 caproic</td>
<td>0.048 ± 0.028</td>
<td>0.024 ± 0.022</td>
<td>&lt;.01</td>
<td>2.0</td>
</tr>
<tr>
<td colspan="5">Medium-chain acylcarnitines</td>
</tr>
<tr>
<td> C8 caprilic</td>
<td>0.100 ± 0.063</td>
<td>0.046 ± 0.071</td>
<td>&lt;.01</td>
<td>2.2</td>
</tr>
<tr>
<td> C10 capric</td>
<td>0.183 ± 0.135</td>
<td>0.057 ± 0.089</td>
<td>&lt;.01</td>
<td>3.2</td>
</tr>
<tr>
<td> C10:1</td>
<td>0.116 ± 0.066</td>
<td>0.043 ± 0.056</td>
<td>&lt;.01</td>
<td>2.7</td>
</tr>
<tr>
<td> C12 lauric</td>
<td>0.025 ± 0.02</td>
<td>0.011 ± 0.012</td>
<td>&lt;.01</td>
<td>2.3</td>
</tr>
<tr>
<td> C14 myristic</td>
<td>0.054 ± 0.036</td>
<td>0.030 ± 0.029</td>
<td>&lt;.01</td>
<td>1.8</td>
</tr>
<tr>
<td> C14:1</td>
<td>0.038 ± 0.034</td>
<td>0.018 ± 0.017</td>
<td>&lt;.01</td>
<td>2.1</td>
</tr>
<tr>
<td colspan="5">Long-chain acylcarnitines</td>
</tr>
<tr>
<td> C16 palmitic</td>
<td>0.367 ± 0.252</td>
<td>0.166 ± 0.139</td>
<td>&lt;.01</td>
<td>2.2</td>
</tr>
<tr>
<td> C18 stearic</td>
<td>0.197 ± 0.103</td>
<td>0.088 ± 0.067</td>
<td>&lt;.01</td>
<td>2.2</td>
</tr>
<tr>
<td colspan="5">Odd short-chain acylcarnitines</td>
</tr>
<tr>
<td> C3 propionic</td>
<td>0.315 ± 0.171</td>
<td>0.278 ± 0.336</td>
<td>.62</td>
<td>1.1</td>
</tr>
<tr>
<td> C5 valeric</td>
<td>0.140 ± 0.091</td>
<td>0.103 ± 0.090</td>
<td>.14</td>
<td>1.4</td>
</tr>
<tr>
<td colspan="5">Dicarboxylic acylcarnitines</td>
</tr>
<tr>
<td> Malonic (C3)</td>
<td>0.169 ± 0.111</td>
<td>0.050 ± 0.066</td>
<td>&lt;.01</td>
<td>3.4</td>
</tr>
<tr>
<td> Glutaric (C5)</td>
<td>0.109 ± 0.054</td>
<td>0.059 ± 0.035</td>
<td>&lt;.01</td>
<td>1.9</td>
</tr>
<tr>
<td> Carnitine, free</td>
<td>10.62 ± 5.69</td>
<td>6.67 ± 4.81</td>
<td>&lt;.01</td>
<td>1.6</td>
</tr>
<tr>
<td colspan="5">Amino acids</td>
</tr>
<tr>
<td> Gly</td>
<td>268 ± 141</td>
<td>173 ± 132</td>
<td>&lt;.01</td>
<td>1.6</td>
</tr>
<tr>
<td> Ala, Sar</td>
<td>188 ± 81</td>
<td>107 ± 77</td>
<td>&lt;.01</td>
<td>1.8</td>
</tr>
<tr>
<td> Val</td>
<td>68 ± 30</td>
<td>47 ± 38</td>
<td>&lt;.04</td>
<td>1.4</td>
</tr>
<tr>
<td> Leu, Ile, Hpr</td>
<td>101 ± 34</td>
<td>64 ± 50</td>
<td>&lt;.01</td>
<td>1.6</td>
</tr>
<tr>
<td> Tyr</td>
<td>46.1 ± 23.6</td>
<td>25.6 ± 19.1</td>
<td>&lt;.01</td>
<td>1.8</td>
</tr>
<tr>
<td> Phe</td>
<td>40.1 ± 22.2</td>
<td>26.6 ± 18.7</td>
<td>&lt;.02</td>
<td>1.5</td>
</tr>
<tr>
<td> Met</td>
<td>7.33 ± 5.35</td>
<td>3.49 ± 2.74</td>
<td>&lt;.01</td>
<td>2.1</td>
</tr>
<tr>
<td colspan="5">Amino acids circulating in the urea cycle</td>
</tr>
<tr>
<td> Arg</td>
<td>18.2 ± 15.0</td>
<td>17.3 ± 20.5</td>
<td>.86</td>
<td>1.1</td>
</tr>
<tr>
<td> Cit</td>
<td>21.8 ± 14.4</td>
<td>19.6 ± 20.3</td>
<td>.65</td>
<td>1.1</td>
</tr>
<tr>
<td> Orn, Asn</td>
<td>35.2 ± 29.7</td>
<td>20.1 ± 17.2</td>
<td>&lt;.03</td>
<td>1.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0148607112443260">
<p>Values are means ± SD. Ala, alanine; Arg, arginine; Asn, asparagine; Cit, citrulline; Gly, glycine; Hpr, hydroxyproline; Ile, isoleucine; Leu, leucine; Met, metionine; Orn, ornithine; Phe, phenylalanine; Sar, sarcosine; Tyr, tyrosine; Val, valine.</p>
</fn>
<fn id="table-fn10-0148607112443260">
<label>a</label>
<p>Statistical difference and ratio between the study group and the enteral nutrition (EN) control group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section13-0148607112443260">
<title>Day-to-Day Fluctuation in the Study Group After Refeeding</title>
<p>The highest day-to-day variation of carnitine fatty acids after refeeding was observed within days 3–6 after EN commencement. In some patients, extreme variations were observed. The day-to-day variations in amino acids were lower than those of the carnitine fatty acids. The amino acid concentration showed a general incline toward the fourth day after EN commencement, and thereafter a clear decline was observed (data are not presented).</p>
</sec>
<sec id="section14-0148607112443260">
<title>Metabolite Values in the Deceased Patients</title>
<p>Seven patients (26%) died during the first month after commencing refeeding (study group). While on food deprivation before commencing refeeding (baseline), the carnityl–fatty acid concentrations of C2, C4, and C6 in these 7 patients were higher by 1.5- to 1.9-fold compared with those observed in the survivors (of the same study group). The sum of these 3 weighted concentrations showed a significant difference (<italic>P</italic> &lt; .01). A similar effect for these 3 metabolites was also observed for the maximal value observed within 1 week following refeeding (<italic>P</italic> &lt; .01; data not presented).</p>
</sec>
</sec>
<sec id="section15-0148607112443260" sec-type="discussion">
<title>Discussion</title>
<p>We have shown the effect of food deprivation and refeeding on blood carnitine fatty acids and free amino acids in frail elderly patients. On food deprivation, most of fatty acid concentrations in the study group were higher than in the EN control group, which comprised patients fed by EN for a prolonged period. During refeeding, blood carnitine fatty acids decreased significantly, whereas for the amino acids, there was a consistent trend of an increase toward the fourth day after EN commencement. The refeeding caused dynamic variations in all metabolites within the follow-up period of the first week after commencing refeeding.</p>
<p>The effects of food deprivation and refeeding were shown previously in healthy volunteers; shortly after refeeding, an immediate decrease in free fatty acids was observed.<sup><xref ref-type="bibr" rid="bibr19-0148607112443260">19</xref><xref ref-type="bibr" rid="bibr20-0148607112443260"/>-<xref ref-type="bibr" rid="bibr21-0148607112443260">21</xref></sup> However, in the studies with healthy participants, the refeeding effect was observed in the free fatty acid fraction, which has a concentration about 170 times higher than the fraction of carnitine fatty acids. However, the fraction of carnitine fatty acids is the most dynamic one in the cellular metabolism of the fatty compounds because it is directly involved in the oxidation and the elongation cycles occurring in the mitochondrion and the peroxisome. Even so, while blood fluctuation is only mirrored by intraorganelle fluctuation, we showed that the tiny amount of all blood lipids (about 0.04% of the total lipids) was highly affected by food deprivation and refeeding.</p>
<p>Fatty acid metabolism is only a small fragment of the whole cellular metabolism, which comprises a large number of enzymes and their control mechanisms, metabolite fluxes, transporting and hormone activities, and many other compounds sharing the cellular metabolism. The fluctuations in the carnitine fatty acids exemplify the thorough instability in cellular metabolism on refeeding. We presume that many other cellular metabolites, particularly the intraorganelle ones, fluctuate at much higher amplitudes on refeeding. Although healthy individuals may tolerate such instability, for some of our most frail patients, such instability may be fatal.</p>
<p>Long-chain free fatty acids were shown to induce proinflammatory responses and significantly affect the growth and viability of the endothelial cells.<sup><xref ref-type="bibr" rid="bibr22-0148607112443260">22</xref></sup> The long-chain fatty acids—namely, palmitic and stearic acids—were also remarkably increased on food deprivation (<xref ref-type="table" rid="table3-0148607112443260">Table 3</xref>). Therefore, the deleterious outcome of long-chain fatty acids should be carefully considered when formulating the solution for refeeding.</p>
<p>The most dramatic effect of the refeeding was viewed in the higher fluctuations of capric acid (C10) and less for C8 and C12. These fluctuations may be caused by a delay in the restoration of MCAD (medium-chain acyl-CoA dehydrogenase) activity, the main enzyme that oxidizes medium-chain fatty acids. Supporting our finding, in patients with severe deficiency of MCAD (the most common defect of fatty acid oxidation), even following brief food deprivation, the risk of metabolic crisis is up to 25%.<sup><xref ref-type="bibr" rid="bibr23-0148607112443260">23</xref>,<xref ref-type="bibr" rid="bibr24-0148607112443260">24</xref></sup> In studies performed with isolated brain mitochondria, higher concentrations of C8 and C10 caused uncoupling of the oxidative phosphorylation and a marked mitochondrial swelling, which presumably resulted in neuropathology.<sup><xref ref-type="bibr" rid="bibr25-0148607112443260">25</xref></sup> When the cellular metabolism shifts from a low to a high level of metabolite influxes, many enzymatic systems (activities and controls) must adapt to the new metabolic steady state, but some enzymes such as MCAD probably have a low capability for a fast adaptation.</p>
<p>On food deprivation, the concentrations of blood amino acids were only slightly affected except for methionine and arginine. Besides their role in protein turnover (cycle of synthesis and degradation), these 2 amino acids have a major role in other metabolic cycles for the supply of 1-carbon units (methionine) and in the urea cycle (arginine). Both cycles might be depressed on food deprivation, resulting in elevation in these 2 amino acids. Amino acids, particularly the essential amino acids, are probably the most stable blood metabolites on food deprivation and thus ensure a continuous protein synthesis for sustaining cell survival. On food deprivation, preservation of serum amino acid is maintained by a continuous breakdown (degradation) of the less critical proteins for survival such as blood albumin or muscle proteins.<sup><xref ref-type="bibr" rid="bibr26-0148607112443260">26</xref>,<xref ref-type="bibr" rid="bibr27-0148607112443260">27</xref></sup></p>
<p>On refeeding, an ample supply of amino acids is provided, which the frail organism is unable to cope with and to direct the higher flux for protein synthesis. The marked decrease in arginine might be caused by a higher urea cycle activity of deamination.</p>
<p>The first week on refeeding is probably the most critical period for adaptation toward a stable state of normal metabolite influxes. This may be supported by the highest fluctuations in amino acids observed during days 3–5 after refeeding.</p>
<p>Following our previous study,<sup><xref ref-type="bibr" rid="bibr5-0148607112443260">5</xref></sup> we are now more aware of the hazards of refeeding and therefore start refeeding in our frail patients with an initial rate of 10 kcal/kg/d and with a gradual increase afterwards. Such an energy flux is much lower than the most prevailing guidelines of 20 kcal/kg,<sup><xref ref-type="bibr" rid="bibr28-0148607112443260">28</xref>,<xref ref-type="bibr" rid="bibr29-0148607112443260">29</xref></sup> whereas the Royal College of Surgeons of England has suggested a rate of 10 kcal/kg for patients at risk of refeeding syndrome.<sup><xref ref-type="bibr" rid="bibr30-0148607112443260">30</xref></sup> Recently, an even lower flux indication of 5 kcal/kg was suggested for critically ill patients.<sup><xref ref-type="bibr" rid="bibr31-0148607112443260">31</xref></sup> Despite the low energy flux on refeeding in the present study, we still had a mortality rate of 25% within the first month following refeeding. We assume that higher energy fluxes (such as 20 kcal/d) may produce higher metabolite fluctuations with probably a higher risk of mortality.</p>
<sec id="section16-0148607112443260">
<title>Limitations of the Present Study</title>
<p>As a pioneer study in the topic of metabolomics and EN, some limitations have arisen in the present study, such as the absence of reference values of the metabolites for the frail elderly. We could not determine free fatty acids, which would require daily blood withdrawal, due to ethics restrictions. And finally, the allocation of the control group is biased because they are the survivors of the critical period of the first month following refeeding. We presume that these limitations did not obscure the main effects of food deprivation and the refeeding that we have shown in the present study.</p>
</sec>
</sec>
<sec id="section17-0148607112443260" sec-type="conclusions">
<title>Conclusion</title>
<p>As care of critically ill patients grows more complex, so does the breadth of knowledge required.<sup><xref ref-type="bibr" rid="bibr32-0148607112443260">32</xref></sup> Measurement of even chain length carnitine fatty acids (C2–C12) might be helpful for the evaluation of malnutrition and preventing refeeding syndrome. Such measurement may provide a measurable tool and indication for energy flux and formula composition on refeeding.<sup><xref ref-type="bibr" rid="bibr31-0148607112443260">31</xref></sup> These conclusions are not confined to the frail elderly but also to the infants undergoing refeeding.<sup><xref ref-type="bibr" rid="bibr33-0148607112443260">33</xref><xref ref-type="bibr" rid="bibr34-0148607112443260"/>-<xref ref-type="bibr" rid="bibr35-0148607112443260">35</xref></sup></p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607112443260">
<label>1.</label>
<citation citation-type="web">
<collab>Business Insights Ltd</collab>. <article-title>Opportunities and key players in clinical nutrition: the market for enteral, parenteral and infant nutrition in the US and the EU</article-title>. <month>June</month> <year>2009</year>. <ext-link ext-link-type="uri" xlink:href="http://www.globalbusinessinsights.com/content/rbcn0001m.pdf">http://www.globalbusinessinsights.com/content/rbcn0001m.pdf</ext-link></citation>
</ref>
<ref id="bibr2-0148607112443260">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Palecek</surname><given-names>EJ</given-names></name>
<name><surname>Teno</surname><given-names>JM</given-names></name>
<name><surname>Casarett</surname><given-names>DJ</given-names></name><etal/>
</person-group>. <article-title>Comfort feeding only: a proposal to bring clarity to decision-making regarding difficulty with eating for persons with advanced dementia</article-title>. <source>J Am Geriatr Soc</source>. <year>2010</year>;<volume>58</volume>:<fpage>580</fpage>-<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr3-0148607112443260">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schnitker</surname><given-names>MA</given-names></name>
<name><surname>Matman</surname><given-names>PE</given-names></name>
<name><surname>Bliss</surname><given-names>TL</given-names></name>
</person-group>. <article-title>A clinical study of malnutrition in Japanese prisoners of war</article-title>. <source>Ann Intern Med</source>. <year>1951</year>;<volume>35</volume>:<fpage>69</fpage>-<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr4-0148607112443260">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schofield</surname><given-names>C</given-names></name>
<name><surname>Ashworth</surname><given-names>A</given-names></name>
</person-group>. <article-title>Why have mortality rates for severe malnutrition remained so high?</article-title> <source>Bull World Health Organ</source>. <year>1996</year>;<volume>74</volume>:<fpage>223</fpage>-<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr5-0148607112443260">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lubart</surname><given-names>E</given-names></name>
<name><surname>Leibovitz</surname><given-names>A</given-names></name>
<name><surname>Dror</surname><given-names>Y</given-names></name>
<name><surname>Katz</surname><given-names>E</given-names></name>
<name><surname>Segal</surname><given-names>R</given-names></name>
</person-group>. <article-title>Mortality after nasogastric tube feeding initiation in long-term care elderly with oropharyngeal dysphagia: the contribution of refeeding syndrome</article-title>. <source>Gerontology</source>. <year>2009</year>;<volume>55</volume>:<fpage>393</fpage>-<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr6-0148607112443260">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jensen</surname><given-names>GL</given-names></name>
<name><surname>Mirtallo</surname><given-names>J</given-names></name>
<name><surname>Compher</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Adult starvation and disease-related malnutrition: a proposal for etiology-based diagnosis in the clinical practice setting from the International Consensus Guideline Committee</article-title>. <source>Clin Nutr</source>. <year>2010</year>;<volume>29</volume>:<fpage>151</fpage>-<lpage>153</lpage>.</citation>
</ref>
<ref id="bibr7-0148607112443260">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marik</surname><given-names>PE</given-names></name>
<name><surname>Bedigian</surname><given-names>MK</given-names></name>
</person-group>. <article-title>Refeeding hypophosphatemia in critically ill patients in an intensive care unit: a prospective study</article-title>. <source>Arch Surg</source>. <year>1996</year>;<volume>131</volume>:<fpage>1043</fpage>-<lpage>1047</lpage>.</citation>
</ref>
<ref id="bibr8-0148607112443260">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marinella</surname><given-names>MA</given-names></name>
</person-group>. <article-title>The refeeding syndrome and hypophosphatemia</article-title>. <source>Nutr Rev</source>. <year>2003</year>;<volume>61</volume>:<fpage>320</fpage>-<lpage>323</lpage>.</citation>
</ref>
<ref id="bibr9-0148607112443260">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stanga</surname><given-names>Z</given-names></name>
<name><surname>Brunner</surname><given-names>A</given-names></name>
<name><surname>Leuenberger</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Nutrition in clinical practice—the refeeding syndrome: illustrative cases and guidelines for prevention and treatment</article-title>. <source>Eur J Clin Nutr</source>. <year>2008</year>;<volume>62</volume>:<fpage>687</fpage>-<lpage>694</lpage>.</citation>
</ref>
<ref id="bibr10-0148607112443260">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Houten</surname><given-names>SM</given-names></name>
<name><surname>Wanders</surname><given-names>RJA</given-names></name>
</person-group>. <article-title>A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation</article-title>. <source>J Inherit Metab Dis</source>. <year>2010</year>;<volume>33</volume>:<fpage>469</fpage>-<lpage>477</lpage>.</citation>
</ref>
<ref id="bibr11-0148607112443260">
<label>11.</label>
<citation citation-type="web">
<collab>HMDB</collab>: <article-title>Human Metabolome Database Version 2.5</article-title>. <ext-link ext-link-type="uri" xlink:href="http://www.hmdb.ca">http://www.hmdb.ca</ext-link></citation>
</ref>
<ref id="bibr12-0148607112443260">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Adams</surname><given-names>SH</given-names></name>
<name><surname>Hoppel</surname><given-names>CL</given-names></name>
<name><surname>Lok</surname><given-names>KH</given-names></name><etal/>
</person-group>. <article-title>Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid β-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women</article-title>. <source>J Nutr</source>. <year>2009</year>;<volume>139</volume>:<fpage>1073</fpage>-<lpage>1081</lpage>.</citation>
</ref>
<ref id="bibr13-0148607112443260">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arduini</surname><given-names>A</given-names></name>
<name><surname>Bonomini</surname><given-names>M</given-names></name>
<name><surname>Savica</surname><given-names>V</given-names></name><etal/>
</person-group>. <article-title>Carnitine in metabolic disease: potential for pharmacological intervention</article-title>. <source>Pharmacol Ther</source>. <year>2008</year>;<volume>120</volume>:<fpage>149</fpage>-<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr14-0148607112443260">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barrows</surname><given-names>BR</given-names></name>
<name><surname>Parks</surname><given-names>EJ</given-names></name>
</person-group>. <article-title>Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2006</year>;<volume>91</volume>:<fpage>1446</fpage>-<lpage>1452</lpage>.</citation>
</ref>
<ref id="bibr15-0148607112443260">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Somanchi</surname><given-names>M</given-names></name>
<name><surname>Tao</surname><given-names>X</given-names></name>
<name><surname>Mullin</surname><given-names>GE</given-names></name>
</person-group>. <article-title>The facilitated early enteral and dietary management effectiveness trial in hospitalized patients with malnutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2010</year>;<volume>35</volume>:<fpage>209</fpage>-<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr16-0148607112443260">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clarfield</surname><given-names>AM</given-names></name>
<name><surname>Monette</surname><given-names>J</given-names></name>
<name><surname>Bergman</surname><given-names>H</given-names></name><etal/>
</person-group>. <article-title>Enteral feeding in end-stage dementia: comparison of religious, ethnic, and national differences in Canada and Israel</article-title>. <source>J Gerontol A Biol Sci Med Sci</source>. <year>2006</year>;<volume>61</volume>:<fpage>621</fpage>-<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr17-0148607112443260">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leistra</surname><given-names>E</given-names></name>
<name><surname>Willeboordse</surname><given-names>F</given-names></name>
<name><surname>Van Bokhorst</surname><given-names>MAE</given-names></name>
<etal/>
</person-group>. <article-title>Predictors for achieving protein and energy requirements in undernourished hospital patients</article-title>. <source>Clin Nutr</source>. <year>2011</year>;<volume>30</volume>:<fpage>484</fpage>-<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr18-0148607112443260">
<label>18.</label>
<citation citation-type="book">
<source>NeoLynx Research 4.0 Application: Manager User’s Guide</source>. <publisher-loc>Milford, MA</publisher-loc>: <publisher-name>Waters Corporation</publisher-name>; <year>2002</year>.</citation>
</ref>
<ref id="bibr19-0148607112443260">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Korbonits</surname><given-names>M</given-names></name>
<name><surname>Blaine</surname><given-names>D</given-names></name>
<name><surname>Elia</surname><given-names>M</given-names></name>
<name><surname>Powell-Tuck</surname><given-names>J</given-names></name>
</person-group>. <article-title>Metabolic and hormonal changes during the refeeding period of prolonged fasting</article-title>. <source>Eur J Endocrinol</source>. <year>2007</year>;<volume>157</volume>:<fpage>157</fpage>-<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr20-0148607112443260">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ruge</surname><given-names>T</given-names></name>
<name><surname>Hodson</surname><given-names>L</given-names></name>
<name><surname>Cheeseman</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Fasted to fed trafficking of fatty acids in human adipose tissue reveals a novel regulatory step for enhanced fat storage</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2009</year>;<volume>94</volume>:<fpage>1781</fpage>-<lpage>1788</lpage>.</citation>
</ref>
<ref id="bibr21-0148607112443260">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>X</given-names></name>
<name><surname>Peter</surname><given-names>A</given-names></name>
<name><surname>Fritsche</surname><given-names>J</given-names></name><etal/>
</person-group>. <article-title>Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at?</article-title> <source>Am J Physiol Endocrinol Metab</source>. <year>2009</year>;<volume>296</volume>:<fpage>E384</fpage>-<lpage>E393</lpage>.</citation>
</ref>
<ref id="bibr22-0148607112443260">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harvey</surname><given-names>KA</given-names></name>
<name><surname>Walker</surname><given-names>CL</given-names></name>
<name><surname>Pavlina</surname><given-names>TM</given-names></name><etal/>
</person-group>. <article-title>Long-chain saturated fatty acids induce pro-inflammatory responses and impact endothelial cell growth</article-title>. <source>Clin Nutr</source>. <year>2010</year>;<volume>29</volume>:<fpage>492</fpage>-<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr23-0148607112443260">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Modre-Osprian</surname><given-names>R</given-names></name>
<name><surname>Osprian</surname><given-names>I</given-names></name>
<name><surname>Tilg</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Dynamic simulations on the mitochondrial fatty acid beta-oxidation network</article-title>. <source>BMC Sys Biol</source>. <year>2009</year>;<volume>3</volume>:<fpage>2</fpage>.</citation>
</ref>
<ref id="bibr24-0148607112443260">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lehotay</surname><given-names>DC</given-names></name>
<name><surname>Lepage</surname><given-names>L</given-names></name>
<name><surname>Thompson</surname><given-names>JR</given-names></name>
<name><surname>Rockman-Greenberg</surname><given-names>C</given-names></name>
</person-group>. <article-title>Blood acylcarnitine levels in normal newborns and heterozygotes for medium-chain acyl-CoA dehydrogenase deficiency: a relationship between genotype and biochemical phenotype?</article-title> <source>J Inherit Metab Dis</source>. <year>2004</year>;<volume>27</volume>:<fpage>81</fpage>-<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr25-0148607112443260">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schuck</surname><given-names>PF</given-names></name>
<name><surname>Ferreira</surname><given-names>GDC</given-names></name>
<name><surname>Tonin</surname><given-names>AM</given-names></name><etal/>
</person-group>. <article-title>Evidence that the major metabolites accumulating in medium-chain acyl-CoA dehydrogenase deficiency disturb mitochondrial energy homeostasis in rat brain</article-title>. <source>Brain Res</source>. <year>2009</year>;<volume>1296</volume>:<fpage>117</fpage>-<lpage>126</lpage>.</citation>
</ref>
<ref id="bibr26-0148607112443260">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hammarqvist</surname><given-names>F</given-names></name>
<name><surname>Andersson</surname><given-names>K</given-names></name>
<name><surname>Luo</surname><given-names>JL</given-names></name>
<name><surname>Wernerman</surname><given-names>J</given-names></name>
</person-group>. <article-title>Free amino acid and glutathione concentrations in muscle during short-term starvation and refeeding</article-title>. <source>Clin Nutr</source>. <year>2005</year>;<volume>24</volume>:<fpage>236</fpage>-<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr27-0148607112443260">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoneda</surname><given-names>T</given-names></name>
<name><surname>Yoshikawa</surname><given-names>M</given-names></name>
<name><surname>Fu</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Plasma levels of amino acids and hypermetabolism in patients with chronic obstructive pulmonary disease</article-title>. <source>Nutrition</source>. <year>2001</year>;<volume>17</volume>:<fpage>95</fpage>-<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr28-0148607112443260">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kreymann</surname><given-names>KG</given-names></name>
<name><surname>Berger</surname><given-names>MM</given-names></name>
<name><surname>Deutz</surname><given-names>NEP</given-names></name>
<etal/>
</person-group>. <article-title>ESPEN Guidelines on Enteral Nutrition: intensive care</article-title>. <source>Clin Nutr</source>. <year>2006</year>;<volume>25</volume>:<fpage>210</fpage>-<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr29-0148607112443260">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bankhead</surname><given-names>R</given-names></name>
<name><surname>Boullata</surname><given-names>J</given-names></name>
<name><surname>Brantley</surname><given-names>S</given-names></name><etal/>
</person-group>. <collab>A.S.P.E.N</collab>. <article-title>enteral nutrition practice recommendations</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>;<fpage>122</fpage>-<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr30-0148607112443260">
<label>30.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Stroud</surname><given-names>M</given-names></name>
<name><surname>Baldwin</surname><given-names>C</given-names></name>
<name><surname>Bradnam</surname><given-names>V</given-names></name><etal/>
</person-group>. <source>Nutrition Support in Adults: Oral Nutrition Support, Enteral Tube Feeding and Parenteral Nutrition</source>. <publisher-loc>London</publisher-loc>: <publisher-name>National Collaborating Centre for Acute Care at The Royal College of Surgeons of England</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr31-0148607112443260">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Boateng</surname><given-names>AA</given-names></name>
<name><surname>Sriram</surname><given-names>K</given-names></name>
<name><surname>Meguid</surname><given-names>MM</given-names></name><etal/>
</person-group>. <article-title>Refeeding syndrome: treatment considerations based on collective analysis of literature case reports</article-title>. <source>Nutrition</source>. <year>2010</year>;<volume>26</volume>:<fpage>156</fpage>-<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr32-0148607112443260">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miller</surname><given-names>KR</given-names></name>
<name><surname>Kiraly</surname><given-names>LN</given-names></name>
<name><surname>Lowen</surname><given-names>CC</given-names></name><etal/>
</person-group>. <article-title>Can we feed? A mnemonic to merge nutrition and intensive care assessment of the critically ill patient</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2011</year>;<volume>35</volume>:<fpage>643</fpage>-<lpage>659</lpage>.</citation>
</ref>
<ref id="bibr33-0148607112443260">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cahill</surname><given-names>NE</given-names></name>
<name><surname>Murch</surname><given-names>L</given-names></name>
<name><surname>Jeejeebhoy</surname><given-names>K</given-names></name><etal/>
</person-group>. <article-title>When early enteral feeding is not possible in critically ill patients: results of a multicenter observational study</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2010</year>;<volume>35</volume>;<fpage>160</fpage>-<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr34-0148607112443260">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhan</surname><given-names>MK</given-names></name>
<name><surname>Bhandari</surname><given-names>N</given-names></name>
<name><surname>Bahl</surname><given-names>R</given-names></name>
</person-group>. <article-title>Management of the severely malnourished child: perspective from developing countries</article-title>. <source>BMJ</source>. <year>2003</year>;<volume>326</volume>:<fpage>146</fpage>-<lpage>151</lpage>.</citation>
</ref>
<ref id="bibr35-0148607112443260">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Afzal</surname><given-names>NA</given-names></name>
<name><surname>Addai</surname><given-names>S</given-names></name>
<name><surname>Fagbemi</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Refeeding syndrome with enteral nutrition in children: a case report, literature review and clinical guidelines</article-title>. <source>Clin Nutr</source>. <year>2002</year>;<volume>21</volume>:<fpage>515</fpage>-<lpage>520</lpage>.</citation>
</ref></ref-list>
</back>
</article>